🔍

JSLL - Jeena Sikho

📊 NSE: JSLL 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 8:36

📢 Recent Corporate Announcements

Jeena Sikho Lifecare Amends Insider Trading and Fair Disclosure Code

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 09 Mar 2026, 12:33 PM

Jeena Sikho Lifecare Limited (JSLL) has updated its internal policies regarding the handling of Unpublished Price Sensitive Information (UPSI). The Board of Directors approved these amendments on March 9, 2026, to ensure compliance with Regulations 8 and 9 of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The revised code governs how designated persons and their relatives trade company securities and defines legitimate purposes for sharing information. This is a standard governance update aimed at strengthening internal controls and transparency.

Board approved amendments to the Code of Fair Disclosure and Internal Procedures on March 9, 2026
Compliance aligned with Regulations 8 and 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015
Policy covers monitoring and reporting of trading by designated persons and their immediate relatives
Updated Legitimate Purpose Policy included in the revised framework to prevent information leakage

💡 This is a routine regulatory update and requires no immediate action. Investors should view this as a positive step toward maintaining corporate governance standards.

Jeena Sikho Lifecare to Participate in Arihant Capital Investor Conference on March 11, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 05:30 PM

Jeena Sikho Lifecare Limited (JSLL) has announced its participation in the Arihant Capital Bharat Connect Conference - Rising Stars 2026. The virtual group meeting is scheduled for March 11, 2026, at 12:00 Noon. Key management personnel, including the Managing Director and CFO, will represent the company to interact with analysts and institutional investors. The company has clarified that no unpublished price sensitive information will be shared during this session.

Virtual group meeting scheduled for March 11, 2026, at 12:00 Noon
Participation in the Arihant Capital Bharat Connect Conference - Rising Stars 2026
Top management attendance including MD Manish Grover and CFO Nanak Chand
Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

💡 Investors should monitor the company's website or exchange filings for any post-conference presentations or transcripts to gain insights into management's outlook. No immediate action is required as this is a routine investor engagement event.

JSLL Publishes 6 Ayurvedic Research Case Studies in International Medical Journals

🟢 POSITIVE ⭐ 4/10

OTHER 📅 23 Feb 2026, 02:35 PM

Jeena Sikho Lifecare Limited (JSLL) has announced the publication of five case studies and one case report in the International Journal of Advanced Research (IJAR) and the Journal of Ayurveda and Integrated Medical Sciences (JAIMS). The research, co-authored by the company's Managing Director and senior consultants, provides clinical evidence for Ayurvedic treatments in Chronic Kidney Disease, Type 2 Diabetes, and Liver diseases. This move is aimed at establishing scientific credibility and evidence-based validation for the company's treatment protocols. Such publications are critical for building brand trust in the alternative medicine sector.

Publication of 5 case studies and 1 case report in peer-reviewed medical journals.
Research covers critical health areas including Chronic Kidney Disease reversal and Type 2 Diabetes management.
Authored by JSLL's Managing Director and senior medical experts to validate clinical practices.
Focuses on demonstrating biochemical outcomes for Fatty Liver and Chronic Liver Disease through Ayurveda.

💡 Investors should view this as a positive step toward building long-term brand equity and clinical credibility. While not an immediate financial driver, it strengthens the company's competitive position in the wellness industry.

JSLL Dehradun Hospital Receives NABH Accreditation Valid Until January 2029

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 19 Feb 2026, 01:19 PM

Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certification for its Dehradun facility. This accreditation specifically covers Panchakarma services at the Jakhan, Dehradun location and is valid until January 05, 2029. While this does not represent a physical expansion or capacity increase, it validates the company's adherence to high-quality healthcare standards and patient safety. Such certifications are crucial for building brand trust and potentially qualifying for government and insurance empanelments in the future.

Awarded NABH accreditation for Dehradun Hospital (Jakhan) specifically for Panchakarma services.
The certification (No. AH-2026-0429) is valid for approximately three years until January 05, 2029.
Signifies adherence to nationally recognized standards for quality healthcare delivery and patient safety.
The accreditation occurred in the ordinary course of business and does not involve immediate capacity enhancement.

💡 This is a positive development for long-term brand equity and service quality assurance. Investors should monitor if this accreditation leads to higher patient footfall or new insurance tie-ups for the Dehradun facility.

Jeena Sikho Lifecare Approves Q3 FY26 Unaudited Financial Results

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 12:24 PM

Jeena Sikho Lifecare Limited (JSLL) has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on February 7, 2026, and concluded with the submission of the limited review report by statutory auditors. This announcement confirms the company's adherence to SEBI Listing Regulations 30 and 33. Investors should now focus on the detailed financial tables to assess the company's performance in the wellness and lifecare sector.

Board approved unaudited standalone and consolidated results for the quarter ended December 31, 2025.
Statutory Auditors issued a Limited Review Report for the nine-month period ending December 2025.
The board meeting was conducted efficiently, starting at 04:05 P.M. and concluding at 04:35 P.M.
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.

💡 Investors should analyze the detailed financial statements for revenue growth and EBITDA margins once the full report is accessed. Monitor the stock for any price volatility following the earnings release.

Jeena Sikho Lifecare Releases Q3 FY 2025-26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 09 Feb 2026, 07:25 PM

Jeena Sikho Lifecare Limited (JSLL) has released the audio recording of its earnings conference call held on February 9, 2026. The call addressed the financial performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure transparency. Investors can now access the management's detailed discussion on the company's financial health and future outlook via the provided link.

Earnings conference call conducted on February 9, 2026, for Q3 FY 2025-26 results.
Discussion covered financial performance for the nine-month period ended December 31, 2025.
Audio recording link made publicly available on the company's official website.
Compliance filing submitted under Regulations 30 and 46 of SEBI (LODR) Regulations, 2015.

💡 Investors should listen to the recording to understand management's commentary on operational performance and future growth guidance. No immediate action is required as this is a routine procedural update.

JSLL Q3 FY26 Results: Revenue Up 92% YoY, PAT Surges 405% to ₹66.73 Crore

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 08 Feb 2026, 02:25 PM

Jeena Sikho Lifecare Limited (JSLL) delivered exceptional Q3 FY26 performance, with revenue growing 92% YoY to ₹221.66 crore. Profitability saw a massive boost as PAT surged 405% YoY to ₹66.73 crore, supported by EBITDA margins expanding from 26% to 45%. The growth was driven by a 247% YoY increase in OPD patient volumes and an 84% rise in IPD volumes. The company is aggressively expanding with 475+ beds in the pipeline, bringing total capacity towards 2,800 beds.

Revenue from operations increased 92% YoY to ₹221.66 crore in Q3 FY26.
PAT skyrocketed 405% YoY to ₹66.73 crore with PAT margins reaching 30%.
EBITDA margins expanded significantly to 45% compared to 26% in Q3 FY25.
OPD, COD, and Video-Call patient volumes grew 247% YoY to 4.34 lakhs.
Current operational capacity is 2,290 beds with 475+ additional beds under development.

💡 Investors should view the massive margin expansion and volume growth as a sign of high operational leverage and scalability. The company's transition to the mainboard and its aggressive bed expansion pipeline make it a strong growth candidate in the Ayurvedic healthcare sector.

Jeena Sikho Lifecare Approves Q3 FY26 Unaudited Standalone and Consolidated Financial Results

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 07 Feb 2026, 07:05 PM

Jeena Sikho Lifecare Limited (JSLL) has announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved both standalone and consolidated unaudited results during their meeting on February 7, 2026. The filing includes the Limited Review Report from statutory auditors, ensuring regulatory compliance under SEBI guidelines. Investors should now focus on the detailed financial statements to evaluate the company's growth and margin performance in the healthcare sector.

Board approved unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025.
Statutory auditors provided a Limited Review Report for the nine-month period ending December 2025.
The board meeting was conducted and concluded within a 30-minute window (04:05 P.M. to 04:35 P.M.).
Compliance maintained as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should scrutinize the detailed profit and loss statements and balance sheet figures to assess the company's operational efficiency. Compare the Q3 results with previous quarters to identify any seasonal trends or growth momentum in the lifecare business.

Jeena Sikho Lifecare Board Approves Unaudited Q3 and Nine-Month FY26 Financial Results

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 07 Feb 2026, 06:55 PM

Jeena Sikho Lifecare Limited (JSLL) held a board meeting on February 7, 2026, to approve its financial performance for the period ending December 31, 2025. The board cleared both standalone and consolidated unaudited results, supported by a limited review report from statutory auditors. This meeting marks the official release of Q3 FY26 performance data to the National Stock Exchange and BSE. Investors should now examine the detailed profit and loss statements to evaluate the company's operational efficiency and growth trajectory.

Board approved unaudited standalone and consolidated financial results for the quarter ended December 31, 2025.
Approval granted for the financial results covering the nine-month period ending December 31, 2025.
Statutory Auditors issued a limited review report on the submitted financial statements.
The board meeting was conducted efficiently, lasting 30 minutes from 4:05 P.M. to 4:35 P.M. IST.

💡 Investors should review the detailed financial tables once published to analyze revenue growth and margin trends. Compare these results against previous quarters to determine if the company is maintaining its growth momentum in the lifecare sector.

Jeena Sikho Lifecare Commences Operations at Two New Hospitals in Siliguri and Bhagalpur

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 04 Feb 2026, 06:51 PM

Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at two new hospital facilities in Siliguri, West Bengal, and Bhagalpur, Bihar, effective February 3, 2026. The Siliguri facility adds 35 beds and 29 rooms, while the Bhagalpur unit adds 25 beds and 18 rooms to the company's healthcare network. Both facilities occupy 10,000 sq. ft. each and include dedicated OPD services. This expansion follows through on proposals initiated in 2025, demonstrating the company's commitment to scaling its physical infrastructure in the Eastern region.

Commenced operations at two new hospitals in West Bengal and Bihar on February 3, 2026
Siliguri facility features 35 beds, 29 rooms, and 3 OPDs across 10,000 sq. ft.
Bhagalpur facility features 25 beds, 18 rooms, and 2 OPDs across 10,000 sq. ft.
Total capacity addition of 60 beds and 47 rooms across the two new locations
Execution of expansion plans within approximately one year of initial proposal

💡 Investors should view this as a positive operational milestone that will likely contribute to revenue growth in the coming quarters. Monitor the occupancy rates and the company's ability to scale these new centers profitably.

JSLL to Engage with 25+ Institutional Investors at Nuvama 21st India Conference

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 04 Feb 2026, 03:20 PM

Jeena Sikho Lifecare Limited (JSLL) has scheduled a series of group meetings with over 25 prominent institutional investors and asset management companies on February 10, 2026. The meetings will take place during the Nuvama 21st India Conference at Hotel Grand Hyatt, Mumbai. Participating entities include high-profile names such as PPFAS Mutual Fund, Motilal Oswal AMC, UTI Mutual Fund, and Aditya Birla Sun Life. These interactions are intended to discuss the company's business based on publicly available information, potentially increasing institutional visibility.

Scheduled meetings with 25+ institutional investors and mutual funds on February 10, 2026.
Participation from top-tier funds including PPFAS Mutual Fund, Motilal Oswal AMC, and UTI Mutual Fund.
Four distinct group meeting slots scheduled between 10:00 AM and 1:50 PM.
Interaction organized as part of the Nuvama 21st India Conference in Mumbai.

💡 Investors should monitor for any post-conference analyst reports or increased institutional buying activity. The high level of interest from reputed funds suggests growing institutional confidence in the company's business model.

Jeena Sikho Lifecare to Host Q3 FY26 Earnings Conference Call on February 9, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 04 Feb 2026, 03:17 PM

Jeena Sikho Lifecare Limited (JSLL) has announced its earnings conference call scheduled for Monday, February 9, 2026, at 3:30 PM IST. The management will discuss the company's operational and financial performance for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). The call will feature Managing Director Manish Grover and CFO Nanak Chand, providing an opportunity for analysts to seek clarity on the company's growth trajectory. This follows the board meeting scheduled for February 3, 2026, to approve the financial results.

Earnings call scheduled for February 9, 2026, at 3:30 PM IST following Q3 FY26 results.
Management participants include MD Manish Grover and CFO Nanak Chand.
The session will cover both financial and operational performance for Q3 and 9M FY26.
Dial-in numbers available for India (+91 22 6280 1326) and international markets including USA, UK, Singapore, and Hong Kong.
Call coordinated by Nuvama Wealth Research (Professional Clients Group).

💡 Investors should monitor the Q3 FY26 results release prior to the call and participate to understand the company's expansion plans and margin outlook.

JSLL Reports One-Year Disease-Free Cancer Care Success in Peer-Reviewed Ayush Journal

🟢 POSITIVE ⭐ 6/10

OTHER 📅 22 Jan 2026, 01:16 PM

Jeena Sikho Lifecare Limited (JSLL) has published a clinical case report in the 'Ayush Journal of Integrative Oncology' documenting a successful outcome for a 53-year-old breast cancer survivor. The report highlights a one-year disease-free resolution of recurrent lymphadenopathy achieved through the company's proprietary Ayurvedic protocols and lifestyle modifications. Co-authored by the Managing Director and the R&D team, this publication provides evidence-based validation for JSLL's clinical practices. This move is intended to strengthen the company's credibility in the integrative oncology space and support its research-driven growth strategy.

Published case report in 'Ayush Journal of Integrative Oncology' documents a one-year disease-free status for a post-mastectomy patient.
Clinical resolution was documented via PET-CT scans, providing objective evidence for the efficacy of the Ayurvedic interventions.
The publication was co-authored by Managing Director Acharya Manish Grover and JSLL's Department of Research and Development.
Treatment involved a combination of personalized Ayurvedic formulations, Panchakarma therapies, and a 'Circadian D.I.P. diet'.
The report reflects the company's commitment to advancing Ayurvedic research and evidence-based clinical practices.

💡 Investors should view this as a positive step toward clinical validation of the company's treatments, which enhances brand trust and market positioning. Monitor for further R&D milestones that could drive long-term patient acquisition and revenue growth.

JSLL Approves AED 7.53 Million Unsecured Loan to International Subsidiary

🔵 WATCH ⭐ 6/10

BOARD_MEETING 📅 21 Jan 2026, 07:22 PM

Jeena Sikho Lifecare Limited (JSLL) has approved an unsecured loan of AED 7.53 million to its wholly-owned subsidiary, Jeena Sikho International LLC. The loan, to be disbursed in two tranches, carries an interest rate of 8.5% per annum with a tenure of five years to support the subsidiary's operational requirements. Separately, the company disclosed it has paid fines imposed by the NSE and BSE for past non-compliance with SEBI Regulation 29. This capital infusion suggests a focus on international expansion while the company works to strengthen its internal compliance systems.

Approved an unsecured loan of AED 7.53 million to wholly-owned subsidiary Jeena Sikho International LLC
Loan features an interest rate of 8.5% per annum on a simple interest basis
The loan tenure is set for 5 years from the date of the first disbursement
Paid fines to NSE and BSE for non-compliance with Regulation 29 regarding board meeting intimations
Transaction is confirmed to be on an arm's length basis as a related party transaction

💡 Investors should monitor the growth and revenue contribution of the international subsidiary following this capital infusion. Additionally, keep a watch on the company's future regulatory filings to ensure compliance issues are fully resolved.

Jeena Sikho Lifecare to Acquire 51% Stake in UAE-based Back to Roots Ayurveda for AED 1.53 Million

🟢 POSITIVE ⭐ 8/10

M&A 📅 16 Jan 2026, 05:11 PM

Jeena Sikho Lifecare Limited (JSLL) has announced that its international subsidiary will acquire a 51% controlling stake in Abu Dhabi-based Back to Roots Ayurveda for AED 1.53 million. This acquisition marks a significant step in JSLL's global expansion strategy within the Ayurveda and wellness sector. The target entity has shown rapid growth, with turnover increasing from AED 0.77 million in 2024 to AED 2.5 million in 2025. The transaction is expected to be completed within 2-3 months via cash consideration, making it a step-down subsidiary of JSLL.

Acquisition of 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC for AED 1.53 million.
Target company turnover grew over 220% year-on-year, reaching AED 2.5 million in 2025 from AED 0.77 million in 2024.
The deal establishes a strategic international footprint for JSLL in the UAE's growing wellness and Panchakarma market.
The acquisition is a cash-only transaction expected to be finalized within approximately 2-3 months.
Back to Roots Ayurveda is a relatively new entity, incorporated in December 2023, showing high growth potential.

💡 Investors should look favorably on this international expansion as it diversifies revenue streams into a high-margin wellness market. Monitor the successful integration of the UAE operations and its impact on consolidated profitability in the next fiscal year.

View All JSLL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 66% YoY to INR 190 Cr in Q2 FY26. The product segment grew approximately 78% YoY, while the services segment contributed 50% of the total revenue during the quarter.

Geographic Revenue Split

The company operates across 23 states and 100+ cities in India. Specific percentage contribution per region is not disclosed, but the footprint has expanded to 2,802 beds as of Q2 FY26.

Profitability Margins

Net Profit (PAT) margin stood at 31% in Q2 FY26, an improvement of 810 bps YoY. The company targets a sustainable long-term healthy profit margin of 20% to 25%.

EBITDA Margin

EBITDA margin reached 48% in Q2 FY26, marking a significant increase from 35% in Q2 FY25 and 45% in Q1 FY26. EBITDA grew 129% YoY to INR 92 Cr.

Capital Expenditure

Cash used in investing activities was INR 70.37 Cr in FY25, primarily for property, plant, and equipment (INR 92.34 Cr total PPE). Setup costs for new facilities are optimized at INR 3-4 lakh per bed.

Credit Rating & Borrowing

The company took a debt of INR 10 Cr from a director to meet working capital requirements in FY25. Total borrowings stood at INR 10.73 Cr (INR 0.43 Cr non-current and INR 10.30 Cr current) as of FY25.

⚙️ Operational Drivers

Raw Materials

Ayurveda medicines (exclusively supplied by JSLL to franchises) and Panchakarma equipment. Specific cost percentages for individual raw materials are not disclosed.

Import Sources

Sourced within India to support the 117 facilities across 23 states.

Key Suppliers

JSLL acts as the exclusive supplier of Ayurveda medicines to its 35 franchise-operated clinics and day-care centers.

Capacity Expansion

Current operational capacity is 2,220 beds as of Q2 FY26, with a total of 2,802 beds reached within the first half of the year. Planned expansion targets 7,000 to 10,000 beds within the next 3 to 5 years.

Raw Material Costs

Inventory stood at INR 2.95 Cr in FY25, down from INR 3.50 Cr in FY24. The company uses a capital-light model where medicines are bundled with services.

Manufacturing Efficiency

Bed occupancy was 57% in Q2 FY26. The company aims to increase utilization to 70-80% within the next 6 to 8 months to drive operating leverage.

Logistics & Distribution

The company is actively increasing its distributor chain to support the planned INR 300-500 Cr turnover from OTC and product marketing.

📈 Strategic Growth

Expected Growth Rate

66%

Growth Strategy

Growth will be driven by expanding bed capacity to 10,000 beds, increasing occupancy from 57% to 80%, and launching an OTC product segment targeting INR 300-500 Cr in revenue. The shift from Government Panel to higher-margin private business is also a key driver.

Products & Services

Ayurveda medicines, IPD (In-Patient Department) hospital services, OPD (Out-Patient Department) consultations, Day Care services, and Video-Call consultations.

Brand Portfolio

Jeena Sikho Lifecare Limited (JSLL).

New Products/Services

Introduction of diagnostics and wellness centers, alongside a major push into the OTC (Over-The-Counter) product market.

Market Expansion

Expansion into 23 states and 100+ cities, with recent analyst meets in Singapore (Dec 2025) to attract international institutional investors.

Strategic Alliances

Franchise model for 35 clinics/day-care centers where JSLL provides doctors and medicines while franchisees manage operations.

🌍 External Factors

Industry Trends

Growing trust and preference for alternative healthcare (Ayurveda) in India, evidenced by a 57% YoY increase in IPD and 67% YoY increase in OPD volumes.

Competitive Landscape

JSLL competes in the healthcare and Ayurveda sector, positioning itself through integrated services (clinics to hospitals) and product sales.

Competitive Moat

Capital-light hub-and-spoke model with low setup costs (INR 3-4 lakh per bed) and a 3-year average ROCE of 71%, providing a significant competitive advantage in scaling.

Macro Economic Sensitivity

Performance is subject to changes in the Indian macroeconomic environment and regulatory landscape for alternative healthcare.

Consumer Behavior

Increasing patient preference for bundled services (products + treatment) and digital health (121% YoY growth in video consultations).

⚖️ Regulatory & Governance

Industry Regulations

Compliance with Ind-AS accounting standards following migration to the Main Board in 2025. Appointment of M/s. Ankur Singh & Associates as Secretarial Auditor for FY26-FY30.

⚠️ Risk Analysis

Key Uncertainties

Material differences in actual results may arise from unforeseen changes in the regulatory landscape or macroeconomic environment. Government debtor delays pose a working capital risk.